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3D

:   three‐dimensional

ASMA

:   alpha smooth muscle actin

CD31

:   cluster of differentiation 31

CD34

:   cluster of differentiation 34

Col‐IV

:   collagen‐IV

CRISPR

:   clustered regularly‐interspaced short palindromic repeats

DAPI

:   4′,6‐diamidino‐2‐phenylindole

DsRed

:   a red fluorescent protein

EGFP

:   enhanced green fluorescent protein

EMCN

:   endomucin

EP

:   endpoints

FLK‐1

:   fetal liver kinase‐1

FLT‐1

:   FMS‐like tyrosine kinase‐1

FPALM

:   photo‐activated localization microscopy

GFP

:   green fluorescent protein

HSC

:   hematopoietic stem cells

IB4

:   griffonia simplicifolia lectin I isolectin B4

MSC

:   mesenchymal stem cells

NG2

:   neural/glial antigen 2

OCT

:   optical coherence tomography

PDGFRβ

:   platelet‐derived growth factor receptor beta

PECAM

:   platelet endothelial cell adhesion molecule (CD31)

RAVE

:   rapid analysis of vessel elements

RFP

:   red fluorescent protein (eg, DsRed)

SSR

:   sum of squared residuals

Tie1

:   tyrosine kinase with immunoglobulin‐like and EGF‐like homology

Tie2

:   angiopoietin‐1 receptor

VAF

:   vessel area fraction

VE‐cadherin/VE‐cad

:   vascular endothelial cadherin

VEGFR

:   vascular endothelial growth factor receptor

vWf

:   Von Willebrand factor

1. INTRODUCTION {#micc12520-sec-0001}
===============

The microvasculature plays a plethora of key roles in maintaining tissue homeostasis, including modulating oxygen transport,[1](#micc12520-bib-0001){ref-type="ref"} nutrient delivery, inflammation response,[2](#micc12520-bib-0002){ref-type="ref"} and wound healing.[3](#micc12520-bib-0003){ref-type="ref"} Structural changes to the microvascular architecture have been shown to profoundly regulate these fundamental biologic processes.[4](#micc12520-bib-0004){ref-type="ref"} Therefore, characterization of the complex changes in spatial structure of the microvascular architecture gives a better understanding of the roles microvessels play in pathogenesis, maintenance, prevention, and amelioration of diseases. Indeed, the importance of the microvasculature has long been appreciated in diseases such as small vessel disease,[5](#micc12520-bib-0005){ref-type="ref"} coronary microvascular disease,[6](#micc12520-bib-0006){ref-type="ref"} and the abundance of complications associated with diabetes.[7](#micc12520-bib-0007){ref-type="ref"} However, recent research has indicated that the microvasculature also plays key roles in the top eight causes of death in the United States[8](#micc12520-bib-0008){ref-type="ref"} (Figure [1](#micc12520-fig-0001){ref-type="fig"}) and many others, including (1) heart disease: impaired infarct wound healing,[9](#micc12520-bib-0009){ref-type="ref"} reduced oxygenation,[10](#micc12520-bib-0010){ref-type="ref"} pulmonary hypertension in pre‐capillary and post‐capillary vessels[11](#micc12520-bib-0011){ref-type="ref"}; (2) cancer: pathological angiogenesis,[12](#micc12520-bib-0012){ref-type="ref"} enriched microvessel permeability,[13](#micc12520-bib-0013){ref-type="ref"} significant route for metastasis[14](#micc12520-bib-0014){ref-type="ref"}; (3) lower respiratory disease: capillary dropout,[15](#micc12520-bib-0015){ref-type="ref"} reduced muscle oxygenation,[16](#micc12520-bib-0016){ref-type="ref"} airway rigidity from vasodilation[17](#micc12520-bib-0017){ref-type="ref"}; (4) stroke: impaired microvascular flow patterns[18](#micc12520-bib-0018){ref-type="ref"} and reduced oxygenation,[19](#micc12520-bib-0019){ref-type="ref"} pericyte constriction of capillaries,[20](#micc12520-bib-0020){ref-type="ref"} dropout of functioning capillaries[21](#micc12520-bib-0021){ref-type="ref"}; (5) unintentional injuries: angiogenesis,[22](#micc12520-bib-0022){ref-type="ref"} clot formation,[23](#micc12520-bib-0023){ref-type="ref"} immune cell recruitment[24](#micc12520-bib-0024){ref-type="ref"}; (6) Alzheimer\'s: attenuated vasodilation response,[25](#micc12520-bib-0025){ref-type="ref"} amyloid angiopathy,[26](#micc12520-bib-0026){ref-type="ref"} and tissue hypoxia[25](#micc12520-bib-0025){ref-type="ref"}; (7) diabetes mellitus: capillary permeability, pericyte dropout, capillary dropout[27](#micc12520-bib-0027){ref-type="ref"}; and (8) pneumonia and influenzas: capillary permability,[28](#micc12520-bib-0028){ref-type="ref"} immune cell recruitment,[28](#micc12520-bib-0028){ref-type="ref"} and impaired lung oxygen transport.[29](#micc12520-bib-0029){ref-type="ref"} Additionally, the microvasculature is recognized as one of the most promising routes of drug delivery[30](#micc12520-bib-0030){ref-type="ref"} by enabling direct targeting of microvascular endothelial cells with intravascularly injected drugs to exert profound therapeutic effects in disease conditions.[31](#micc12520-bib-0031){ref-type="ref"} The overall import of the microvasculature in biomedical research is quickly approaching that of the nearly ubiquitous roles that the immune system plays in basic organismal processes[32](#micc12520-bib-0032){ref-type="ref"}, [33](#micc12520-bib-0033){ref-type="ref"} and disease development,[34](#micc12520-bib-0034){ref-type="ref"} and future research focused on microvascular structure, function, and adaptations promises profound opportunities for curing human disease.

![The significance of the microvasculature in top causes of death and disease in United States. Top eight classes of fatal disease or injury with the fraction of annual deaths in the United States. Included with each malady are three highlighted fundamental roles the microvasculature plays with initiation, maintenance, or treatment (see main text for references)](MICC-26-na-g001){#micc12520-fig-0001}

In this review, we highlight new key developments and survey contemporary and classical models of the microvasculature, along with techniques to label and image microvessels at high resolution where the complete microvascular structure is captured. Therefore, microvascular research that fails to resolve the smallest‐sized vascular structures is omitted or given less emphasis, such as fundus imaging of the retina[35](#micc12520-bib-0035){ref-type="ref"} and other clinical imaging methods. Although a subset of the modalities covered can yield 3D images, we focus on analysis of 2D projections of 3D vessel networks since it can be universally applied to all microvascular imaging modalities, 2D representations of 3D networks retain much of their information,[36](#micc12520-bib-0036){ref-type="ref"} and 2D methods for quantification of vessel architecture can be extended to three dimensions,[37](#micc12520-bib-0037){ref-type="ref"} although we do comment on the potential pitfalls of using 2D metrics to characterize 3D microvascular structures. Furthermore, many of the 3D modalities for microvascular imaging have reduced axial resolution compared to lateral, and practical considerations of acquisition time usually lead to further reduced axial sampling.[38](#micc12520-bib-0038){ref-type="ref"} The currently available programs to analyze and quantify microvascular structures are also covered, along with constructive proposals for improvement in this area. While each topic covered could be a detailed examination on its own, this review is meant to offer a basic orientation of the technological options available for microvascular research and a perspective on analytical techniques to increase scientific rigor as science faces an ongoing crisis in reproducibility.[39](#micc12520-bib-0039){ref-type="ref"}

2. MARKERS AND MODELS TO STUDY MICROVASCULAR NETWORK ARCHITECTURE {#micc12520-sec-0002}
=================================================================

The study of the complex architecture of microvasculature requires proper labeling and visualization of microvessels, using either a marker for particular cell types, unique basement membrane constituents, and/or labeling perfused microvessels via the intravascular injection of a dye or fluorescently tagged antibody to visualize blood flow through microvessel lumens.[40](#micc12520-bib-0040){ref-type="ref"}, [41](#micc12520-bib-0041){ref-type="ref"}, [42](#micc12520-bib-0042){ref-type="ref"} All of these labeling methods provide a means of contrasting microvascular architectures with the surrounding tissue when paired with a suitable imaging modality. The particular choice of vascular marker and imaging method should be carefully evaluated based on the biological questions being examined and determined based on requirements for resolution, signal to noise, tissue penetration depth, imaging location in terms of in vivo/ex vivo, and labeled cell specificity.[38](#micc12520-bib-0038){ref-type="ref"} The relative importance of the various labeling and imaging considerations for microvascular visualization depends on the nature of the research and biological questions asked. For example, with investigations focusing on angiogenesis and subsets of vessel types, cell labeling of specific subpopulations is essential, while for studies characterizing blood flow, accurate vessel diameter and connectivity between vessel segments have greater significance. Moreover, effective pairing of these technologies with a particular imaging approach requires an understanding of the fundamental strengths and weaknesses of the options available.

2.1. Markers of microvasculature {#micc12520-sec-0003}
--------------------------------

A critically important aspect of studying blood vessels is carefully tailoring biological interpretations and conclusions to appropriately correspond to the specific cell types or structures visualized (Table [1](#micc12520-tbl-0001){ref-type="table"}). An example that illustrates incongruity between data and interpretation is when vessels are labeled via perfusion of fluorescent dye[43](#micc12520-bib-0043){ref-type="ref"} and general conclusions are made about vascular remodeling, disregarding changes in structure of nonperfused vessels, vessel neosprouts, and regressing vessels.[44](#micc12520-bib-0044){ref-type="ref"} Even with specifically worded conclusions, focusing on findings that only quantify portions of the microvascular architecture represents an incomplete analysis and may omit significant remodeling events. Another key example is the use of superfused IB4 lectin, a marker commonly used to label blood vessels that also labels pericyte[45](#micc12520-bib-0045){ref-type="ref"} and macrophages[46](#micc12520-bib-0046){ref-type="ref"} (Figure [2](#micc12520-fig-0002){ref-type="fig"}A). Especially in development, many papers prematurely conclude changes occur in vascular architecture based on lectin staining[47](#micc12520-bib-0047){ref-type="ref"}, [48](#micc12520-bib-0048){ref-type="ref"} while omitting the issue that a mix of cell types are labeled, especially with the inability to differentiate structures between pericyte and endothelial cells. Studies that use Col‐IV staining to quantify microvascular architecture[49](#micc12520-bib-0049){ref-type="ref"} have similar shortcomings, labeling not just blood vessels[50](#micc12520-bib-0050){ref-type="ref"} (Figure [2](#micc12520-fig-0002){ref-type="fig"}B), but other cell types such as pericytes and fibroblasts.[51](#micc12520-bib-0051){ref-type="ref"} Additionally, Col‐IV also marks thin bridges between capillaries previously referred to as Col‐IV sleeves,[52](#micc12520-bib-0052){ref-type="ref"} string vessels,[53](#micc12520-bib-0053){ref-type="ref"} and acellular capillaries[54](#micc12520-bib-0054){ref-type="ref"} in various tissues such as retina,[54](#micc12520-bib-0054){ref-type="ref"} brain,[55](#micc12520-bib-0055){ref-type="ref"} and muscle. Especially in the retina, this feature is interpreted as a sign of collapsed or regressed vessels, yet this has never actually been established. There is a clear separation between the two structures in thickness (Figure [2](#micc12520-fig-0002){ref-type="fig"}C) and with the cross‐sectional pixel intensity profile between lumenized vessels and Col‐IV tracks (Figure [2](#micc12520-fig-0002){ref-type="fig"}D), with a lack of structures found in an intermediate or transitioning phenotype. An alternative hypothesis would be pericytes extending off‐vessel processes[56](#micc12520-bib-0056){ref-type="ref"} and secreting Col‐IV.[57](#micc12520-bib-0057){ref-type="ref"} For instances where the cell type responsible for an immunostained structure is not established with confidence, we caution interpreting results are cell‐type specific, even if previously stated in the literature.

###### 

Markers of the Microvasculature

  ***Diagram***                                                                                                           ![](MICC-26-na-g007.jpg "image")                                                         ![](MICC-26-na-g008.jpg "image")                      ![](MICC-26-na-g009.jpg "image")                      ![](MICC-26-na-g010.jpg "image")
  ----------------------- ----------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **PECAM/ CD31**         Surface[136](#micc12520-bib-0136){ref-type="ref"}                                               ✓[137](#micc12520-bib-0137){ref-type="ref"}                                              ✗[138](#micc12520-bib-0138){ref-type="ref"}           ✗[139](#micc12520-bib-0139){ref-type="ref"}           Platelets, T‐cells. leukocytes[137](#micc12520-bib-0137){ref-type="ref"}
  **IB4 Lectin**          Var.[140](#micc12520-bib-0140){ref-type="ref"}, [141](#micc12520-bib-0141){ref-type="ref"}      ✓[46](#micc12520-bib-0046){ref-type="ref"}, [142](#micc12520-bib-0142){ref-type="ref"}   ✓[45](#micc12520-bib-0045){ref-type="ref"}            ✓[143](#micc12520-bib-0143){ref-type="ref"}           Macrophages[144](#micc12520-bib-0144){ref-type="ref"}, microglia[46](#micc12520-bib-0046){ref-type="ref"}, monocytes[145](#micc12520-bib-0145){ref-type="ref"}
  **Col‐IV**              ECM[40](#micc12520-bib-0040){ref-type="ref"}                                                    ✓[146](#micc12520-bib-0146){ref-type="ref"}                                              ✓[147](#micc12520-bib-0147){ref-type="ref"}           ✓[148](#micc12520-bib-0148){ref-type="ref"}           Fibroblasts[149](#micc12520-bib-0149){ref-type="ref"}, MSCs[150](#micc12520-bib-0150){ref-type="ref"}
  **Laminin**             ECM[151](#micc12520-bib-0151){ref-type="ref"}                                                   ✓[152](#micc12520-bib-0152){ref-type="ref"}                                              ✓[152](#micc12520-bib-0152){ref-type="ref"}           ✓[152](#micc12520-bib-0152){ref-type="ref"}           Fibroblasts[153](#micc12520-bib-0153){ref-type="ref"}, epithelial cells[154](#micc12520-bib-0154){ref-type="ref"}
  **CD34**                Surface[136](#micc12520-bib-0136){ref-type="ref"}                                               ✓[155](#micc12520-bib-0155){ref-type="ref"}                                              ✗[156](#micc12520-bib-0156){ref-type="ref"}           ✗[157](#micc12520-bib-0157){ref-type="ref"}           MSCs, HSCs, muscle satellite cells, fibrocytes[158](#micc12520-bib-0158){ref-type="ref"}
  **VE‐cadherin**         Surface[138](#micc12520-bib-0138){ref-type="ref"}                                               ✓[138](#micc12520-bib-0138){ref-type="ref"}                                              ✗[159](#micc12520-bib-0159){ref-type="ref"}           ✗[160](#micc12520-bib-0160){ref-type="ref"}           None[161](#micc12520-bib-0161){ref-type="ref"}
  **EMCN**                Surface[162](#micc12520-bib-0162){ref-type="ref"}                                               ✓[163](#micc12520-bib-0163){ref-type="ref"}                                              ✗[164](#micc12520-bib-0164){ref-type="ref"}           ✗[164](#micc12520-bib-0164){ref-type="ref"}           Putative hematopoietic progenitor cells[165](#micc12520-bib-0165){ref-type="ref"}
  **vWf**                 Internal[166](#micc12520-bib-0166){ref-type="ref"}                                              ✓[167](#micc12520-bib-0167){ref-type="ref"}                                              ✗[167](#micc12520-bib-0167){ref-type="ref"}           ✗[168](#micc12520-bib-0168){ref-type="ref"}           Megakaryocytes[166](#micc12520-bib-0166){ref-type="ref"}
  **aSMA**                Internal[169](#micc12520-bib-0169){ref-type="ref"}                                              ✗[169](#micc12520-bib-0169){ref-type="ref"}                                              ✓[170](#micc12520-bib-0170){ref-type="ref"}           ✓[171](#micc12520-bib-0171){ref-type="ref"}           Fibroblasts[172](#micc12520-bib-0172){ref-type="ref"}, perisinusoidal cells[169](#micc12520-bib-0169){ref-type="ref"}
  **MYH11**               Internal[173](#micc12520-bib-0173){ref-type="ref"}                                              ✗[173](#micc12520-bib-0173){ref-type="ref"}                                              ✓[174](#micc12520-bib-0174){ref-type="ref"}           ✓[175](#micc12520-bib-0175){ref-type="ref"}           None[174](#micc12520-bib-0174){ref-type="ref"}
  **NG2**                 Surface[176](#micc12520-bib-0176){ref-type="ref"}                                               ✗[176](#micc12520-bib-0176){ref-type="ref"}                                              ✓[157](#micc12520-bib-0157){ref-type="ref"}           ✓[156](#micc12520-bib-0156){ref-type="ref"}           Microglia[170](#micc12520-bib-0170){ref-type="ref"}, macrophages, oligodendrocyte porogenitors[177](#micc12520-bib-0177){ref-type="ref"}
  **N‐Cadherin**          Surface[178](#micc12520-bib-0178){ref-type="ref"}                                               ✓[179](#micc12520-bib-0179){ref-type="ref"}                                              ✓[159](#micc12520-bib-0159){ref-type="ref"}           ✓[180](#micc12520-bib-0180){ref-type="ref"}           MSCs[181](#micc12520-bib-0181){ref-type="ref"}, fibroblasts[159](#micc12520-bib-0159){ref-type="ref"}, osteoblasts[159](#micc12520-bib-0159){ref-type="ref"}
  **Desmin**              Internal[182](#micc12520-bib-0182){ref-type="ref"}                                              ✗[168](#micc12520-bib-0168){ref-type="ref"}                                              ✓[183](#micc12520-bib-0183){ref-type="ref"}           ✓[156](#micc12520-bib-0156){ref-type="ref"}           Interstitial cells, muscle satellite cells[158](#micc12520-bib-0158){ref-type="ref"}
  **PDGFRβ**              Surface[184](#micc12520-bib-0184){ref-type="ref"}                                               ✗[185](#micc12520-bib-0185){ref-type="ref"}                                              ✓[156](#micc12520-bib-0156){ref-type="ref"}           ✓[156](#micc12520-bib-0156){ref-type="ref"}           MSCs[156](#micc12520-bib-0156){ref-type="ref"}, fibroblasts[156](#micc12520-bib-0156){ref-type="ref"} **,** some neurons[156](#micc12520-bib-0156){ref-type="ref"}
  **Perf. PECAM**         Surface[186](#micc12520-bib-0186){ref-type="ref"}, [187](#micc12520-bib-0187){ref-type="ref"}   Perf.[186](#micc12520-bib-0186){ref-type="ref"}                                          ✗[138](#micc12520-bib-0138){ref-type="ref"}           ✗[138](#micc12520-bib-0138){ref-type="ref"}           Platelets[188](#micc12520-bib-0188){ref-type="ref"}, leukocytes[158](#micc12520-bib-0158){ref-type="ref"}
  **Perf. Neuro‐Trace**   Internal[189](#micc12520-bib-0189){ref-type="ref"}                                              ✗[189](#micc12520-bib-0189){ref-type="ref"}                                              Capillary[186](#micc12520-bib-0186){ref-type="ref"}   ✗[189](#micc12520-bib-0189){ref-type="ref"}           Other neuronal cells when *fixed* (brain)[189](#micc12520-bib-0189){ref-type="ref"}
  **FITC**                Passive[42](#micc12520-bib-0042){ref-type="ref"}                                                Perf.[42](#micc12520-bib-0042){ref-type="ref"}                                           ✗[42](#micc12520-bib-0042){ref-type="ref"}            ✗[42](#micc12520-bib-0042){ref-type="ref"}            None[42](#micc12520-bib-0042){ref-type="ref"}
  **Tie2**                Surface[190](#micc12520-bib-0190){ref-type="ref"}                                               ✓[64](#micc12520-bib-0064){ref-type="ref"}                                               ✓^**\***^ [64](#micc12520-bib-0064){ref-type="ref"}   ✓^**\***^ [64](#micc12520-bib-0064){ref-type="ref"}   Monocytes, macrophages[67](#micc12520-bib-0067){ref-type="ref"}, HSCs[191](#micc12520-bib-0191){ref-type="ref"}
  **Dextran**             Passive[192](#micc12520-bib-0192){ref-type="ref"}                                               Perf.[192](#micc12520-bib-0192){ref-type="ref"}                                          ✗[192](#micc12520-bib-0192){ref-type="ref"}           ✗[192](#micc12520-bib-0192){ref-type="ref"}           None[193](#micc12520-bib-0193){ref-type="ref"}
  **VEGFR2, FLK‐1**       Surface[194](#micc12520-bib-0194){ref-type="ref"}                                               ✓[194](#micc12520-bib-0194){ref-type="ref"}                                              ✗[139](#micc12520-bib-0139){ref-type="ref"}           ✗[139](#micc12520-bib-0139){ref-type="ref"}           HSCs[195](#micc12520-bib-0195){ref-type="ref"}, macrophages[196](#micc12520-bib-0196){ref-type="ref"}, neurons[197](#micc12520-bib-0197){ref-type="ref"}
  **VEGFR1, FLT‐1**       Surface[198](#micc12520-bib-0198){ref-type="ref"}                                               ✓[198](#micc12520-bib-0198){ref-type="ref"}                                              ✗[199](#micc12520-bib-0199){ref-type="ref"}           ✗[199](#micc12520-bib-0199){ref-type="ref"}           HSCs, macrophages[196](#micc12520-bib-0196){ref-type="ref"}, neurons[197](#micc12520-bib-0197){ref-type="ref"}

EC, endothelial cell, ECM, extracellular matrix; HSC, hematopoietic stem cell, MSC, mesenchymal stem cell, Perf., perfused; PC, pericyte, SMC, smooth muscle cell; Var., various. **Labeling**: yes (✓), no (✗).

*Note:* Table shows general trends, there are exceptions with specific tissues, species, and disease conditions. ^**\***^See main text.
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![Both endothelial cells and pericytes share markers used in the literature for labeling endothelial cells, and Col‐IV tracks, assumed to be regressed vessels, lack a pixel intensity profile indicative of a lumen. (A) Retina capillary with pericyte (NG2, red), IB4 lectin (green), endothelial cells (CD31, yellow), and cell nuclei (DAPI, cyan). (B) Retina capillary with pericyte and endothelial cells labeled with Col‐IV (green; scale bar 10 μm). (C) High‐resolution image of Col‐IV off‐vessel track (star) and lumenized blood vessel (arrow; scale bar 5 μm). (D) Comparison of Col‐IV relative pixel intensity profile across cross‐section of blood vessels and collagen tracks (*P* = 8.11E‐6, 2‐way analysis of variance, N = 10 vessels and tracks, error bars are standard deviation)](MICC-26-na-g002){#micc12520-fig-0002}

Another challenge for marking the microvasculature is identifying effective markers for PCs. Pericytes have no well‐established cross tissue exclusive marker, making them hard to target for analysis,[58](#micc12520-bib-0058){ref-type="ref"} although recent system‐level analyses have revealed novel candidate markers that await confirmation.[59](#micc12520-bib-0059){ref-type="ref"} A major point of contention with pericytes markers includes consensus with ASMA expression in pericytes, which is thought to be absent in pericytes on capillaries throughout some tissues, such as retina.[60](#micc12520-bib-0060){ref-type="ref"} However, recent evidence indicates that this may be a product of how tissue samples are processed: In the retina, it was shown that if standard fixation techniques are used with ASMA staining, capillary pericytes are ASMA‐negative,[61](#micc12520-bib-0061){ref-type="ref"} but if the samples were snap frozen with methanol fixation to prevent actin depolymerization, at least half of capillary pericytes are ASMA‐positive.[61](#micc12520-bib-0061){ref-type="ref"} We suspect that major portions of other canonically known ASMA‐negative pericyte populations across tissues might actually express this marker, and there is a possibility that ASMA is, in fact, a pan marker for pericytes that requires a more sensitive measurement technique to confirm. However, even if ASMA is expressed by all pericytes to some degree, it is not a unique marker for pericytes, because it is also expressed by vascular smooth muscle cells.

Finally, the expression of Tie2 by pericytes has been fiercely debated in the past decades, with extensive characterization of Tie2 expression in cultured pericytes,[62](#micc12520-bib-0062){ref-type="ref"} but a lack of Tie2 expression noted in pericytes in vivo.[63](#micc12520-bib-0063){ref-type="ref"} However, recent evidence has shown that a pericytes‐specific knockout of Tie2 leads to dramatically altered vascular structure, paired with a demonstration of Tie2 acting as a potent pericyte chemokine in vitro,[64](#micc12520-bib-0064){ref-type="ref"} together suggesting that Tie2 signaling may serve an important role in pericyte function. However, this finding awaits confirmation with the development of effective antibodies or other methods to directly label Tie2 in tissue and demonstrate pericyte expression in vivo. This controversy highlights the need to utilize measurement techniques that avoid such complications with variable results from tissue processing, such as fluorescent in‐situ hybridization[65](#micc12520-bib-0065){ref-type="ref"} which measures RNA expression of the target gene directly.

2.2. Animal models with endogenously labeled vasculature {#micc12520-sec-0004}
--------------------------------------------------------

An increasing number of transgenic murine models have been developed to visualize the microvasculature, including those that contain cell‐type specific fluorescent reporters for endothelial cells, smooth muscle cell, and pericytes (Table [2](#micc12520-tbl-0002){ref-type="table"}). We emphasize there is an important limitation of these reporter models that is often ignored: these animal models often only include the proximal endogenous reporter region with the fluorescent reporter, meaning that gene expression behavior from distal enhancers is often lost. An example of this is with Tie2 expression, which has been found in other cell types such as HSCs.[66](#micc12520-bib-0066){ref-type="ref"} and neutrophils, endothelial progenitor cells, macrophages,[67](#micc12520-bib-0067){ref-type="ref"} pericytes, [62](#micc12520-bib-0062){ref-type="ref"} and keratinocytes.[68](#micc12520-bib-0068){ref-type="ref"} Yet the primary Tie2‐GFP mouse model is only known for GFP expression exclusively in endothelial cells,[69](#micc12520-bib-0069){ref-type="ref"} in this case serving as an advantage with a reporter line that appears to selectively label the vasculature and not track other cell types known to have endogenous expression.

###### 

Animal Models to Label Microvasculature

  Name                                                       Species                                                                                      Sub Pop.                                                 Cell Type Overlap
  ---------------------------------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------- -----------------------------------------------------------------------
  Tie2‐GFP                                                   Ms, Zb[200](#micc12520-bib-0200){ref-type="ref"}                                             EC[200](#micc12520-bib-0200){ref-type="ref"}             None[201](#micc12520-bib-0201){ref-type="ref"}
  Tie2‐Cre‐GFP                                               Ms                                                                                           EC[202](#micc12520-bib-0202){ref-type="ref"}             HSCs[203](#micc12520-bib-0203){ref-type="ref"}
  Tie2‐CreERT2‐EGFP                                          Ms                                                                                           EC[204](#micc12520-bib-0204){ref-type="ref"}             None[205](#micc12520-bib-0205){ref-type="ref"}
  VE‐Cad‐Cre‐GFP                                             Ms                                                                                           EC[206](#micc12520-bib-0206){ref-type="ref"}             Lymphatic endothelial cells[206](#micc12520-bib-0206){ref-type="ref"}
  VE‐Cad‐CreERT‐GFP                                          Ms                                                                                           EC[207](#micc12520-bib-0207){ref-type="ref"}             None[208](#micc12520-bib-0208){ref-type="ref"}
  FLT1:GFP                                                   Ms[209](#micc12520-bib-0209){ref-type="ref"}, Zb[210](#micc12520-bib-0210){ref-type="ref"}   EC[210](#micc12520-bib-0210){ref-type="ref"}             Migratory angioblasts[210](#micc12520-bib-0210){ref-type="ref"}
  FLK1:GFP, RFP                                              Ms[211](#micc12520-bib-0211){ref-type="ref"}, Zb[212](#micc12520-bib-0212){ref-type="ref"}   EC[213](#micc12520-bib-0213){ref-type="ref"}             None[212](#micc12520-bib-0212){ref-type="ref"}
  My11‐CreERT‐YFP                                            Ms                                                                                           PC, SMC[174](#micc12520-bib-0174){ref-type="ref"}        None[175](#micc12520-bib-0175){ref-type="ref"}
  PDGFRB‐CreERT2‐TOM                                         Ms                                                                                           PC,SMC[214](#micc12520-bib-0214){ref-type="ref"}         Glial cells[214](#micc12520-bib-0214){ref-type="ref"}
  NG2‐Dsred                                                  Ms                                                                                           PC, SMC[156](#micc12520-bib-0156){ref-type="ref"}        Oligodendrocyte progenitors[215](#micc12520-bib-0215){ref-type="ref"}
  NG2‐Cre‐ERT2M                                              Ms                                                                                           PC, SMC[216](#micc12520-bib-0216){ref-type="ref"}        Oligodendrocyte precursors[205](#micc12520-bib-0205){ref-type="ref"}
  Tie1‐EGFP                                                  Ms                                                                                           Embryonic EC[217](#micc12520-bib-0217){ref-type="ref"}   None[217](#micc12520-bib-0217){ref-type="ref"}
  PDGFb‐CreERT2                                              Ms                                                                                           ECs[218](#micc12520-bib-0218){ref-type="ref"}            None[218](#micc12520-bib-0218){ref-type="ref"}
  β‐Actin‐GFP                                                Ms                                                                                           EC, PC[219](#micc12520-bib-0219){ref-type="ref"}         Not examined[205](#micc12520-bib-0205){ref-type="ref"}
  α‐SMA‐GFP, RFP[220](#micc12520-bib-0220){ref-type="ref"}   Ms                                                                                           Sub. PC, SMC[221](#micc12520-bib-0221){ref-type="ref"}   None[221](#micc12520-bib-0221){ref-type="ref"}
  α‐SMA‐CreERT2                                              Ms                                                                                           Sub. PC, SMC[222](#micc12520-bib-0222){ref-type="ref"}   None[222](#micc12520-bib-0222){ref-type="ref"}

EC, endothelial cell; HSC, hematopoietic stem cell; PC, pericyte; SMC, smooth muscle cell. **Species**: Ms, mouse; Zb, zebrafish.

*Note:* Labeling can vary across tissues, and in most cases not rigorously verified.
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2.3. In vitro and ex vivo models to study the microvasculature {#micc12520-sec-0005}
--------------------------------------------------------------

Over the last century, various models have been used to study the complexity of the microvasculature, including those that utilize cultures of various cell populations, tissue explants, and animal models (Table [3](#micc12520-tbl-0003){ref-type="table"}). Historically, researchers have had to consider significant trade‐offs when choosing between different model systems. In vivo models typically have the best chance of recapitulating human disease since pathologies are heavily influenced by the complex interplay of a multitude of cell types.[70](#micc12520-bib-0070){ref-type="ref"} However, this benefit comes at a cost: In vivo models are usually limited by throughput, exhibit high cost in time and resources, and imaging techniques restricted by limitations with sedation duration, subject restraint, and detector scan speed. Furthermore, typically any intervention short of a cell‐specific knockout of an implicated gene will not establish cellular mechanism, which can take years to generate in an in vivo model. In vitro models typically exhibit much higher throughput and have a wider range of available analysis tools to characterize the system,[71](#micc12520-bib-0071){ref-type="ref"} but at the cost of greater simplification and abstraction of tissue structure and disease conditions compared to in vivo, such as lacking various cell types or blood flow.

###### 

Model Systems of Microvascular Architectures

  Name/ Tissue                               Type         Species                                                                                                                                    Throughput   Noninvasive Setup   Δ Vaso. Diameter   Timelapse   Adult   Angiogenesis   Network   Lumen   Flow   Mural
  ------------------------------------------ ------------ ------------------------------------------------------------------------------------------------------------------------------------------ ------------ ------------------- ------------------ ----------- ------- -------------- --------- ------- ------ -------
  Chick Chorioallantoic Membrane             *In vivo*    Ch[223](#micc12520-bib-0223){ref-type="ref"}                                                                                               ++           ✗                   ✓                  ✓           ✗       ✓              ✓         ✓       ✓      ✓
  Mesentery                                  *In vivo*    Ms[224](#micc12520-bib-0224){ref-type="ref"}, Rt[225](#micc12520-bib-0225){ref-type="ref"}, Ct[226](#micc12520-bib-0226){ref-type="ref"}   \+           ✗                   ✓                  ✓           ✓       ✓              ✓         ✓       ✓      ✓
  Gluteus Maximus                            *In vivo*    Ms[227](#micc12520-bib-0227){ref-type="ref"}                                                                                               \+           ✗                   ✓                  ✓           ✓       ✓              ✓         ✓       ✓      ✓
  Vessel Segments from Resistance Arteries   *Ex vivo*    Ms[228](#micc12520-bib-0228){ref-type="ref"}, Hm[229](#micc12520-bib-0229){ref-type="ref"}                                                 \+           ✗                   ✓                  ✓           ✓       ✗              ✓         ✓       ✗      ✓
  Skeletal Muscle                            *Ex vivo*    Ms[230](#micc12520-bib-0230){ref-type="ref"}, Rt[231](#micc12520-bib-0231){ref-type="ref"}                                                 \+           ✗                   ✓                  ✓           ✓       ✓              ✓         ✓       ✓      ✓
  Cremaster                                  *In vivo*    Ms[232](#micc12520-bib-0232){ref-type="ref"}, Rt[233](#micc12520-bib-0233){ref-type="ref"}                                                 \+           ✓                   ✓                  ✓           ✓       ✓              ✓         ✓       ✓      ✓
  Retina                                     *Ex vivo*    Ms                                                                                                                                         \+           ✓                   ✗                  ✗           ✓       ✓              ✓         ✓       ✓      ✓
  Embryoid Explant                           *In vivo*    Zb[234](#micc12520-bib-0234){ref-type="ref"}, Ms[235](#micc12520-bib-0235){ref-type="ref"}, Fg[236](#micc12520-bib-0236){ref-type="ref"}   ++           ✗                   ✓                  ✓           ✗       ✓              ✓         ✓       ✓      ✓
  Cornea Limbal                              *In vivo*    Ms[237](#micc12520-bib-0237){ref-type="ref"}                                                                                               \+           ✓                   ✓                  ✓           ✓       ✓              ✓         ✓       ✓      ✓
  Microfluidic EC Chip                       *In vitro*   Var[238](#micc12520-bib-0238){ref-type="ref"}                                                                                              +++          ✗                   ✗                  ✓           \~      ✓              ✓         ✓       ✓      ✗
  EC‐PC Matrix Co‐culture                    *In vitro*   Var[239](#micc12520-bib-0239){ref-type="ref"}, [240](#micc12520-bib-0240){ref-type="ref"}                                                  ++++         ✗                   ✗                  ✓           \~      ✗              ✓         ✓       ✗      ✓
  EC‐PC Transwell                            *In vitro*   Var.[239](#micc12520-bib-0239){ref-type="ref"}                                                                                             ++++         ✗                   ✗                  ✓           \~      ✗              ✗         ✗       ✓      ✓
  EC Culture                                 *In vitro*   Var.[239](#micc12520-bib-0239){ref-type="ref"}                                                                                             ++++         ✗                   ✗                  ✓           \~      ✓              ✓         ✓       ✓      ✗
  Dermal                                     *In vivo*    Ms[44](#micc12520-bib-0044){ref-type="ref"}                                                                                                \+           ✓                   ✓                  ✓           ✓       ✓              ✓         ✓       ✓      ✓
  Developing Retina                          *In vivo*    Ms.[241](#micc12520-bib-0241){ref-type="ref"}                                                                                              \+           ✗                   ✓                  ✗           ✗       ✓              ✓         ✓       ✓      ✓
  Embryoid Body                              *In vivo*    Ms.[242](#micc12520-bib-0242){ref-type="ref"}                                                                                              +++          ✗                   ✗                  ✓           ✗       ✓              ✗         ✗       ✗      ✓
  Brain Explant                              *Ex vivo*    Ms.[243](#micc12520-bib-0243){ref-type="ref"}                                                                                              ++           ✗                   ✓                  ✓           ✓       ✓              ✓         ✓       ✗      ✓
  Retina Explant                             *Ex vivo*    Ms.[244](#micc12520-bib-0244){ref-type="ref"}, [245](#micc12520-bib-0245){ref-type="ref"}, Rt.[246](#micc12520-bib-0246){ref-type="ref"}   ++           ✗                   ✓                  ✓           ✓       ✓              ✓         ✓       ✗      ✓
  Allantois Explant                          *Ex vivo*    Ms.[247](#micc12520-bib-0247){ref-type="ref"}                                                                                              ++           ✗                   ✓                  ✓           ✗       ✓              ✓         ✓       ✗      ✓
  EC Microbeads in Fibrin                    *In vitro*   Var.[248](#micc12520-bib-0248){ref-type="ref"}                                                                                             ++++         ✗                   ✗                  ✓           \~      ✓              ✓         ✓       ✗      ✗

EC, endothelial cell; PC, pericyte. **Species**: Ch, chicken; Ct, cat; Fg, frog; Hm, hamster; Ms, mouse; Rt, rat; Var., various; Zb, zebrafish. **Features**: yes (✓), no (✗), various (\~). **Throughput**: measure of degree of throughput for each protocol. **Noninvasive setup**: if model setup requires an invasive procedure. **Δ Vaso. Diameter**: if vasoconstriction or vasodilation can practically be examined in a real‐time fashion. **Timelapse**: if system can practically be imaged continuously in a real‐time fashion. **Adult**: if tissue analyzed is from adult or embryonic. **Angiogenesis**: if angiogenesis can be observed. **Network**: if model either has existing vascular network or can form a network. **Lumen:** whether vascular structures have a lumen. **Flow**: if vascular structures exhibit flow in model system. **Mural**: if smooth muscle cells and pericytes are included.

*Note:* Table is meant to capture general trends for what is feasible in a standard version of the experiment setup, there are exceptions.

John Wiley & Sons, Ltd

However, the trade‐offs between in vivo and in vitro models are blurring now more than ever. Advances in new imaging techniques allow for in vivo imaging that provides the opportunity for higher throughput and fully temporal measurements in various tissues. The latest in vivo gene editing techniques, such as CRISPR/Cas9,[72](#micc12520-bib-0072){ref-type="ref"} have made targeted genetic alterations easier, yet there are still challenges remaining with regards to efficiency and off‐target binding of genetic payloads.[73](#micc12520-bib-0073){ref-type="ref"} At the same time, advances in 3D bioprinting, biomaterial research, and patient‐specific primary cell culture allow for more advanced in vitro models, although there is still difficulty with cell collection in these systems for subsequent analysis.[71](#micc12520-bib-0071){ref-type="ref"} Indeed, the number of available model systems has been growing, and with the advent of new analysis techniques, the opportunities to collect data from microvascular network architecture have increased dramatically and reveal new prospects for efficient and reproducible data capture.

3. STATE‐OF THE‐ART IMAGING MODALITIES FOR MICROVASCULAR NETWORKS {#micc12520-sec-0006}
=================================================================

There are a vast range of techniques available for imaging the microvasculature, with trade‐offs between resolution, signal penetration, and acquiring multiplexed functional readouts, such as blood flow and tissue oxygenation (Table [4](#micc12520-tbl-0004){ref-type="table"}). Beyond the classical fluorescent‐based imaging modalities that have been a mainstay for imaging microvascular structure, there now exist several new technologies that also quantify microvascular function. Advances in photoacoustic microscopy have recently enabled imaging of a wide range of tissue depots, larger fields of view, and higher resolutions, along with capturing other functional data such as blood flow velocity and tissue oxygenation.[74](#micc12520-bib-0074){ref-type="ref"} The technology behind OCT, an imaging technique based on reflected light and measuring time of flight for photons, has recently improved with resolution to the point where these imaging modalities can successfully image the microvasculature.[75](#micc12520-bib-0075){ref-type="ref"} New super resolution imaging techniques developed in the last decade, such FPALM and stochastic optical reconstruction microscopy, have allowed visualization of structures in details beyond the resolution limit of visible light, allowing for direct imaging of individual proteins and flourophores.[76](#micc12520-bib-0076){ref-type="ref"}

###### 

Imaging Modalities for Vascular Networks

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                           Resolution                                          Z Depth                                                                                      Flow                                               Oxygen   Mechanism   Trade‐offs                                                       
  ------------------------------ --------------------------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------- -------- ----------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bright field                   1 μm[249](#micc12520-bib-0249){ref-type="ref"}      0.25 μm[249](#micc12520-bib-0249){ref-type="ref"}                                            50 μm[38](#micc12520-bib-0038){ref-type="ref"}     ✗        ✗           *Absorbance* [250](#micc12520-bib-0250){ref-type="ref"}          **+** Visualize outlines of cells[250](#micc12520-bib-0250){ref-type="ref"}, low cost\
                                                                                                                                                                                                                                                                                                                           **+** Temporal resolution\
                                                                                                                                                                                                                                                                                                                           **−** Excites fluorophores outside of imaging area[250](#micc12520-bib-0250){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Image is blurred by emission from out‐of‐focus regions[250](#micc12520-bib-0250){ref-type="ref"}

  Fluorescent Widefield          1 μm[251](#micc12520-bib-0251){ref-type="ref"}      0.25 μm[251](#micc12520-bib-0251){ref-type="ref"}                                            50 μm[38](#micc12520-bib-0038){ref-type="ref"}     ✗        ✗           *Fluorescence* [250](#micc12520-bib-0250){ref-type="ref"}        \+ Temporal resolution: milliseconds[252](#micc12520-bib-0252){ref-type="ref"}, low cost\
                                                                                                                                                                                                                                                                                                                           **−** High resolution requires immersion objectives[251](#micc12520-bib-0251){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Image is blurred by emission from out‐of‐focus regions[250](#micc12520-bib-0250){ref-type="ref"}

  Point Scanning Confocal        0.50 μm[251](#micc12520-bib-0251){ref-type="ref"}   0.18 μm[251](#micc12520-bib-0251){ref-type="ref"}                                            100 μm[253](#micc12520-bib-0253){ref-type="ref"}   ✗        ✗           *Fluorescence* [252](#micc12520-bib-0252){ref-type="ref"}        \+ Pin‐hole reduce out‐of‐focus light[250](#micc12520-bib-0250){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           + Temporal resolution: milliseconds[252](#micc12520-bib-0252){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Phototoxicity, photobleaching[254](#micc12520-bib-0254){ref-type="ref"}

  Spinning Disk Confocal         0.75 μm[254](#micc12520-bib-0254){ref-type="ref"}   0.25 nm[254](#micc12520-bib-0254){ref-type="ref"}                                            100 μm[38](#micc12520-bib-0038){ref-type="ref"}    ✗        ✗           *Fluorescence* [252](#micc12520-bib-0252){ref-type="ref"}        \+ Higher FPS compared to point scan[250](#micc12520-bib-0250){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           + Less phototoxic to cell, less photobleaching[250](#micc12520-bib-0250){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Poorer filtering of out‐of‐focus light compared to point scan[250](#micc12520-bib-0250){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Lower resolution, smaller FOV[254](#micc12520-bib-0254){ref-type="ref"}

  Two Photon                     0.4 μm[251](#micc12520-bib-0251){ref-type="ref"}    0.20 μm[251](#micc12520-bib-0251){ref-type="ref"}                                            1 mm[255](#micc12520-bib-0255){ref-type="ref"}     ✗        ✗           *Fluorescent* [256](#micc12520-bib-0256){ref-type="ref"}         \+ Useful for thick specimens (\>200um)[250](#micc12520-bib-0250){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           + Bleaching limited to imaging plane[251](#micc12520-bib-0251){ref-type="ref"}, low light scatter[256](#micc12520-bib-0256){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           + NIR light less phototoxic than VIS\
                                                                                                                                                                                                                                                                                                                           **−** Enhanced heating from NIR light\
                                                                                                                                                                                                                                                                                                                           **−** Broader excitation, pronounced photobleaching[257](#micc12520-bib-0257){ref-type="ref"}

  Photo‐acoustic                 1 μm[258](#micc12520-bib-0258){ref-type="ref"}      10 μm[258](#micc12520-bib-0258){ref-type="ref"}                                              5 mm[259](#micc12520-bib-0259){ref-type="ref"}     ✓        ✓           *Flow, oxygenation* [260](#micc12520-bib-0260){ref-type="ref"}   \+ High contrast and spatial resolution, high framerate[260](#micc12520-bib-0260){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           + Imaging thick tissues (\>1 cm)[260](#micc12520-bib-0260){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Increased resolution at expense of ultrasonic penetration[260](#micc12520-bib-0260){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Comparably low resolution[260](#micc12520-bib-0260){ref-type="ref"}

  Laser Doppler                                                                      1 μm[261](#micc12520-bib-0261){ref-type="ref"}                                               1 mm[261](#micc12520-bib-0261){ref-type="ref"}     ✓        ✗           *Flow* [262](#micc12520-bib-0262){ref-type="ref"}                \+ Live imaging of flow[262](#micc12520-bib-0262){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Long mapping time[262](#micc12520-bib-0262){ref-type="ref"}

  Laser Speckle                                                                      10 μm[263](#micc12520-bib-0263){ref-type="ref"}                                              1 mm[264](#micc12520-bib-0264){ref-type="ref"}     ✓        ✗           *Fluorescence* [265](#micc12520-bib-0265){ref-type="ref"}        \+ Resolution adequate for low‐flow microvasculature[265](#micc12520-bib-0265){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           + Noninvasive, live imaging[265](#micc12520-bib-0265){ref-type="ref"}, real‐time changes in flow[265](#micc12520-bib-0265){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Requires knowledge of blood velocity distribution[262](#micc12520-bib-0262){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Motion artifacts[265](#micc12520-bib-0265){ref-type="ref"}

  Second Harmonic                2.5 μm[266](#micc12520-bib-0266){ref-type="ref"}    0.70 μm[266](#micc12520-bib-0266){ref-type="ref"}                                            300 μm[267](#micc12520-bib-0267){ref-type="ref"}   ✗        ✗           *Auto‐fluorescence* [268](#micc12520-bib-0268){ref-type="ref"}   \+ Three‐dimensional resolution[269](#micc12520-bib-0269){ref-type="ref"}, NIR wavelength\
                                                                                                                                                                                                                                                                                                                           + Label free[267](#micc12520-bib-0267){ref-type="ref"}, Long imaging times[269](#micc12520-bib-0269){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Low image quality in deep tissue[270](#micc12520-bib-0270){ref-type="ref"}

  Optical Coherence Tomography   2 μm[271](#micc12520-bib-0271){ref-type="ref"}      1 μm[271](#micc12520-bib-0271){ref-type="ref"}, [272](#micc12520-bib-0272){ref-type="ref"}   2 mm[253](#micc12520-bib-0253){ref-type="ref"}     ✓        ✗           *Reflectance* [273](#micc12520-bib-0273){ref-type="ref"}         \+ Temporal resolution: seconds[252](#micc12520-bib-0252){ref-type="ref"}, label free[274](#micc12520-bib-0274){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           + Technology contained in endoscopes, handheld probes[271](#micc12520-bib-0271){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Angiography visualizes only flow, not leakage[274](#micc12520-bib-0274){ref-type="ref"}

  RESOLFT, STED                  50 nm[250](#micc12520-bib-0250){ref-type="ref"}     30 nm[275](#micc12520-bib-0275){ref-type="ref"}                                              300 μm[276](#micc12520-bib-0276){ref-type="ref"}   ✗        ✗           *Fluorescence* [252](#micc12520-bib-0252){ref-type="ref"}        \+ Video‐rate, live‐cell imaging[252](#micc12520-bib-0252){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           + Temporal resolution: seconds[252](#micc12520-bib-0252){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Requires highly‐stable fluorophores[252](#micc12520-bib-0252){ref-type="ref"}

  FPALM                          50 nm[250](#micc12520-bib-0250){ref-type="ref"}     20 nm[275](#micc12520-bib-0275){ref-type="ref"}                                                                                                 ✗        ✗           *Fluorescence* [252](#micc12520-bib-0252){ref-type="ref"}        \+ Fast framerate for high resolution[252](#micc12520-bib-0252){ref-type="ref"}, live‐cell imaging[252](#micc12520-bib-0252){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           + Image single molecules/single particle tracking[252](#micc12520-bib-0252){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Requires photo‐switchable fluorophores[252](#micc12520-bib-0252){ref-type="ref"}

  Electron Microscopy            8 nm[277](#micc12520-bib-0277){ref-type="ref"}      1 nm[252](#micc12520-bib-0252){ref-type="ref"}                                               \<1 μm[278](#micc12520-bib-0278){ref-type="ref"}   ✗        ✗           *Fluorescence* [252](#micc12520-bib-0252){ref-type="ref"}        \+ High resolution[252](#micc12520-bib-0252){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Limited labeling options[19](#micc12520-bib-0019){ref-type="ref"}, no temporal resolution[252](#micc12520-bib-0252){ref-type="ref"}, [279](#micc12520-bib-0279){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Restrictive sample prep.[252](#micc12520-bib-0252){ref-type="ref"}, [279](#micc12520-bib-0279){ref-type="ref"}

  Light‐Sheet                    0.75 μm[280](#micc12520-bib-0280){ref-type="ref"}   0.25 μm[280](#micc12520-bib-0280){ref-type="ref"}                                            10 mm[264](#micc12520-bib-0264){ref-type="ref"}    ✗        ✗           *Fluorescence* [280](#micc12520-bib-0280){ref-type="ref"}        \+ Excellent optical sectioning 3D imaging[281](#micc12520-bib-0281){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           + Low bleaching and phototocicity[281](#micc12520-bib-0281){ref-type="ref"}\
                                                                                                                                                                                                                                                                                                                           **−** Restrictive sample prep[281](#micc12520-bib-0281){ref-type="ref"}
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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4. MICROVASCULAR NETWORK ANALYSIS AND QUANTIFICATION {#micc12520-sec-0007}
====================================================

The microvascular network forms a sprawling architecture of interconnected vessels that vascularize nearly all tissues in the body. Such complex spatial networks undergo remodeling in adult tissue as well as embryonic; in quiescence as well as pathologic. Understanding changes in vessel morphology cannot be captured by a single metric to quantify its structure: A range of metrics must be used to summarize various unique characteristics of the network. While previous work has developed a multitude of metrics for quantifying microvascular architecture, we believe that further work must be done in both developing new metrics and demonstrating that a given set of available metrics provide unique and useful information to answer biological questions. To this end, a series of suggestions are proposed to increase scientific rigor and reproducibility of quantifying the complexities of the microvasculature.

4.1. Metrics for quantifying microvascular networks {#micc12520-sec-0008}
---------------------------------------------------

Previous research has developed various metrics for microvascular network analysis (Figure [3](#micc12520-fig-0003){ref-type="fig"}A‐G), including the fraction of image area composed of blood vessels (VAF),[77](#micc12520-bib-0077){ref-type="ref"} blood vessel length normalized by image field of view (vessel length density),[78](#micc12520-bib-0078){ref-type="ref"} average vessel diameter of all vessels or divided by vessel type,[79](#micc12520-bib-0079){ref-type="ref"} density of branchpoints,[80](#micc12520-bib-0080){ref-type="ref"} tortuosity,[81](#micc12520-bib-0081){ref-type="ref"} lacranuity,[78](#micc12520-bib-0078){ref-type="ref"} fractal dimension,[81](#micc12520-bib-0081){ref-type="ref"} and max extra‐vascular diffusion distance to examine tissue oxygen perfusion.[82](#micc12520-bib-0082){ref-type="ref"} Other metrics have been developed outside of this set but not standardized and adopted by consensus. Studies often normalize metrics in different ways, such as measuring branchpoints per image, normalizing to field of view, or normalizing to vessel length. We posit that metrics should be designed to encourage valid comparisons across research studies and should be normalized to facilitate this process. Thus, using a simple metric of vessel length[83](#micc12520-bib-0083){ref-type="ref"} is not as useful as vessel length density, a metric that can be directly compared over a range of spatial resolutions and imaging modalities.

![Basic metrics quantifying the complexities of the microvascular architecture. Visual explanation of metrics that have been used to quantify various aspects of microvessel network architecture, including (A) VAF, (B) vessel length density, (C) vessel diameter, (D) branchpoints density, (E) tortuosity, (F) lacranuity and fractal dimension, (G) extra‐vascular diffusion distance, and (H) vessel segment partitioning](MICC-26-na-g003){#micc12520-fig-0003}

4.2. Architectural features of microvasculature: bridging form and function {#micc12520-sec-0009}
---------------------------------------------------------------------------

Capillary architecture possesses markedly different structures to meet the unique metabolic demands of peripheral tissues,[84](#micc12520-bib-0084){ref-type="ref"} including the radial spoke‐wheel structure of the retina, parallel beds of skeletal muscle, or dense networks of the liver (Figure [4](#micc12520-fig-0004){ref-type="fig"}A‐F). Even within a single tissue such as the retina, there is impressive heterogeneity in microvascular architecture between tissue locations (Figure [4](#micc12520-fig-0004){ref-type="fig"}G‐I). This tissue environment heterogeneity is further reflected by unique endothelial transcriptomes found in each organ[85](#micc12520-bib-0085){ref-type="ref"} and distinct endothelial marker profiles at different parts of the vascular tree.[86](#micc12520-bib-0086){ref-type="ref"}

![Heterogeneity of blood vessel network structure across and within tissue. IB4 lectin Perfused microvessels of (A) heart, (B) diaphragm, (C) skeletal muscle, (D) liver, (E) peritoneal cavity, (F) inguinal fat, and of the three distinct vascular layers of the retina (G‐I; scale bar 50 μm)](MICC-26-na-g004){#micc12520-fig-0004}

With much of biology, function and form are closely interwined[87](#micc12520-bib-0087){ref-type="ref"}: the microvasculature is no exception. A wide range of biological behaviors, including blood vessel growth, regression, dilation, constriction, stability, and permeability, can be mapped to quantitative metrics of microvascular structure and give insight into physiologic and pathological function of the microcirculation (Figure [5](#micc12520-fig-0005){ref-type="fig"}). Beyond the adaptations of microvessel networks to support unique tissue metabolic environments, morphological changes in vessel structure are hallmarks of key vascular remodeling events. Spatial distribution of capillary networks determines spatial heterogeneity of oxygenation and nutrient delivery.[88](#micc12520-bib-0088){ref-type="ref"}, [89](#micc12520-bib-0089){ref-type="ref"} Enriched build‐up of extra‐cellular matrix can indicate a fibrotic response[90](#micc12520-bib-0090){ref-type="ref"} to inflammatory conditions. Increased blood vessel tortuosity can indicate signs of endothelial cell activation and pathological microvascular remodeling and/or ischemia‐induced arterialization in collateral microvessels.[91](#micc12520-bib-0091){ref-type="ref"}

![Bridging form and function: correspondence between microvasculature architecture metrics and biological behaviors. Schematized microvasculature network with various cellular and acellular components (multicolored font) mapped to quantitative image analysis metrics that indicate different aspects of microvascular function (black font)](MICC-26-na-g005){#micc12520-fig-0005}

Moreover, certain quantification metrics may carry unique significance depending on the location analyzed within the vascular tree. For instance, changes in vessel diameter in arterioles suggest changes in vascular smooth muscle cell vasoconstriction to modulate vascular resistance,[92](#micc12520-bib-0092){ref-type="ref"} capillary diameter changes are indicative of changes to pericyte contraction and distribution of flow and oxygenation,[93](#micc12520-bib-0093){ref-type="ref"} and venule dilation suggests changes to blood capacitance (storage)[94](#micc12520-bib-0094){ref-type="ref"} or remodeling in response to inflammation to facilitate leukocyte extravasation from circulation.[95](#micc12520-bib-0095){ref-type="ref"}

4.3. The need for pairing perivascular and microvascular analysis {#micc12520-sec-0010}
-----------------------------------------------------------------

Analyzing changes to the perivascular space can yield just as important insights as the vasculature itself given the close cross‐talk between endothelial cells and smooth muscle cell and pericytes. For example, changes in pericyte density are known to play a key role in the pathogenesis of diabetes,[27](#micc12520-bib-0027){ref-type="ref"} and changes in pericyte locations relative to branchpoints[96](#micc12520-bib-0096){ref-type="ref"} have been associated with changes to stability and sensitization of the microvascular network. We emphasize the need to analyze perivascular behavior as well as microvascular remodeling to truly understand the structure and function of microvascular networks: A common limitation of many studies is to study one or the other in isolation. Most existing software for quantifying microvascular network architecture accomplishes this by evaluating the endothelial network structure. There is one software package that can analyze perivascular cell recruitment to the vasculature through overlap of the two structures.[97](#micc12520-bib-0097){ref-type="ref"} While this metric may be confounded by changes in perivascular or vascular density across study groups, and perivascular cells may associate with the vasculature with minimal channel overlap, this software allows researchers to begin to probe perivascular interactions with the microvasculature. A survey of the published literature reveals that the most common approach for analyzing perivascular cell coverage and/or morphology (eg, of pericytes,[98](#micc12520-bib-0098){ref-type="ref"} smooth muscle cell,[99](#micc12520-bib-0099){ref-type="ref"} or other cell types like macrophages[100](#micc12520-bib-0100){ref-type="ref"} that are known to play key roles in angiogenesis and vessel remodeling[101](#micc12520-bib-0101){ref-type="ref"}) is through manual or basic automated comparisons of thresholded area or nuecleii.[102](#micc12520-bib-0102){ref-type="ref"} For example, basic cell counts can be obtained manually through ImageJ\'s cell[103](#micc12520-bib-0103){ref-type="ref"} counting feature, the multipoint tool,[104](#micc12520-bib-0104){ref-type="ref"} or using its particle analysis set of tools for automated analysis.[104](#micc12520-bib-0104){ref-type="ref"} More extensive positional or morphological investigations of perivascular structures require custom image analysis solutions that have yet to be developed. Automated and quantitative analysis of microvascular networks paired with detailed analysis of smooth muscle and pericyte cell populations could become a standard pipeline that would enable better understanding of microvascular remodeling mechanisms and the development of new therapeutics for microvascular diseases.

4.4. Software packages for quantifying microvascular networks {#micc12520-sec-0011}
-------------------------------------------------------------

Alterations in microvessel network architecture have been used ubiquitously in studying vascular diseases, and there are a multitude of software packages available for quantifying changes in architecture (Table [5](#micc12520-tbl-0005){ref-type="table"}). Three, notably, have been used in a significant number of publications, namely AngioQuant, AngioTool, and RAVE.

###### 

Vessel Network Analysis Tools

  Name                                                                                    Lang.          Application                         Metrics                                                          Validation                                                               Cts   Yr     Cts/yr
  --------------------------------------------------------------------------------------- -------------- ----------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------ ----- ------ --------
  AngioQuant[83](#micc12520-bib-0083){ref-type="ref"}                                     MATLAB         Brightfield, Cell Culture           Segment Count, VL, VA, VAF, Segment Area, BP, BP/Segment Count   QT BD                                                                    104   2005   8
  RAVE[81](#micc12520-bib-0081){ref-type="ref"}                                           MATLAB         Fluorescent, Tissue                 VAF, VLD, VR, FD                                                 QT manually analyzed BD for VAF, VLD, and VR. Basic *In silico* for FD   24    2011   3.4
  Vessel Analysis ImageJ Macro                                                            ImageJ Macro   Brightfield, Tissue                 VAF, VLD                                                         None                                                                     ‐     ‐      ‐
  AngioTool[78](#micc12520-bib-0078){ref-type="ref"}                                      Java, ImageJ   Fluorescent, Tissue                 VAF, SC, VL, VLD, EP, lacunarity, BP/area                        QL manually analyzed BD                                                  111   2011   15.9
  CSAQ[282](#micc12520-bib-0282){ref-type="ref"}                                          *Web Based*    Brightfield, Tissue                 VL, VAF, BP; Contrast, Entropy                                   Manual (BP), QT comparison to AngioQuant                                 24    2008   2.4
  Breast Tumor Microvasculature Reconstruction[82](#micc12520-bib-0082){ref-type="ref"}   MATLAB, JAVA   Micro Ct, Tumor                     VLD, VD, SL, MEVDD, FD, Tortuosity, Flow                         Metrics from BD within literature values                                 17    2013   3.4
  VESGEN 2D[283](#micc12520-bib-0283){ref-type="ref"}                                     Java, ImageJ   Brightfield/ Flourescence, Tissue   VD, VT, FD, VAF, VLD, BP                                         QT BD                                                                    29    2009   3.2

BD, biological data; BP, branchpoints; EP, endpoints; FD, fractal dimension; MEVDD, max extra‐vascular diffusion distance; NS, not specified; QL, qualitative; QT, quantitative; SC, segment count; SL, segment length; VLD, vessel length density; VD, vessel diameter; VR, vessel radius.

John Wiley & Sons, Ltd

AngioQuant has been developed to analyze endothelial networks in vitro, with a focus on quantifying various metrics of tubule formation using bright field images.[83](#micc12520-bib-0083){ref-type="ref"} Recently, it has been adapted for use in evaluating higher resolution datasets of microvascular networks in vivo[105](#micc12520-bib-0105){ref-type="ref"} and in histological samples.[106](#micc12520-bib-0106){ref-type="ref"} Its validation is focused on quantification of in vitro experiments showing trends of changes with various metrics, but no statistical comparisons between study groups. The datasets were not validated against manually analyzed images and there is no analysis included comparing accuracy and overall performance between AngioQuant and other available software packages.

AngioTool is presented as a quick, hands‐off, and reproducible image analysis tool, deployed as an ImageJ plugin, for quantification of microvascular networks in microscopic images.[78](#micc12520-bib-0078){ref-type="ref"} The validation of AngioTool included analyzing biological data from murine hindbrain and retina using various metrics, including visualized vessel segmentation, vessel centerline, and branchpoints presented for qualitative inspection. For quantitative biological validation, endothelial cell explants were cultured and analyzed with two drug treatments that were known to alter vascular structure as a positive control.[78](#micc12520-bib-0078){ref-type="ref"} Additionally, output metrics were validated with a subset of manually counted images in an unblinded fashion with two investigators.

RAVE is an image analysis tool that can be used on a wide array of images[81](#micc12520-bib-0081){ref-type="ref"} to accelerate the unbiased, quantitative analysis of microvasculature architecture. Validation for this tool included comparing automated outputs generated by RAVE to manual analysis of various morphometric parameters for in vivo microvessel networks in murine spinotrapezius muscle tissue and in a xenograph tumor model. A dataset of images was compared to manually processed images with a Bland‐Altman analysis.

4.5. Improving vessel quantification, analysis, and interpretation {#micc12520-sec-0012}
------------------------------------------------------------------

We estimate that these software packages are largely underutilized, based on the high number of published manuscripts that refer to the quantification of microvessel architecture. Indeed, a search on PubMed on relevant terminology (terms used included: microvasculature density, capillary dropout, pericyte dropout; see all terms in Appendix [S1](#micc12520-sup-0001){ref-type="supplementary-material"}) reveals over 120 000 publications to date. While this query includes publications that merely mention the terms searched for, the nearly three order‐of‐magnitude difference between citations of these software programs compared to this large collection of publications suggests that there is an unmet need for vessel architecture analysis beyond the available options, with researchers often resorting to manual ad hoc analysis of microvessel networks, leading to decreased repeatability, comparability, and scientific rigor. We propose the following design criteria for an effective software package:

**Ground truth validation:** A rigorous and complete validation of software requires a comprehensive analysis of multiple types of datasets. This includes an extensive comparison of automated results to manually processed images, not just with output metrics, but also with the pixel‐by‐pixel raw segmentation, skeleton centerline, and branchpoints locations quantified with a combination of false positive rates, false negative rates, Bland‐Altman analysis, and SSR. Ideally, this manual comparison would include multiple study groups with known vascular differences in architecture between them.**Biological validation:** Validating the automated pipeline with several biological datasets with known differences (biological positive controls), ideally from different tissue and/or imaging resolutions, will demonstrate the efficacy of the program in practice. This analysis demonstrates that the program can detect true positives in actual dataset, where a real change is detected between study groups.**In silico validation:** Program development needs to be paired with a validated parameterized computational model that can generate artificial in silico vascular networks[107](#micc12520-bib-0107){ref-type="ref"} to verify that changing basic parameters of the model yields expected changes in metric output with the image analysis pipeline.**Quantitative comparisons between previously developed programs:** The field benefits far less from releasing another "one‐off" vessel image analysis program independent from previous work and instead should test and demonstrate its efficacy compared to existing software. Outputs from each program and manual analysis should be compared, including output metrics, raw segmentation, skeletonization, and branchpoints assignment in the form of false positive and negative error rates, Bland‐Altman analysis, and SSR. Execution time should also be critically evaluated and reported, given the importance of balancing throughput with accuracy.**Standardized metric sets:** Each software program has a unique collection of metrics that are often calculated using different methods. A consensus of metrics needs to be established in the interest of rigor and reproducible science. An example of this would be measuring branchpoints: Some packages display raw counts, while others normalize to image area or vessel length.**Effectiveness of metric collections:** Methods should be developed to not only test and validate each method but also demonstrate their usefulness as a collection in determining changes in the vascular architecture. Analysis needs to be done to show that these new metrics provide unique non‐correlative information compared to existing metrics, utilizing techniques developed from the field of feature selection.[108](#micc12520-bib-0108){ref-type="ref"}**Effect of image quality on output metrics:** An examination needs to be performed with respect to how the program performs when image quality varies between study groups from batch effects, or simply has a high degree of variance. Image quality of the datasets provided with these software packages often appears ideal. High variance with image quality may skew segmentation results and output metrics, so output metrics across a range of image qualities should be examined.**Effect of parameter adjustment:** Some software packages allow for adjustment of key image processing parameters to enhance results, but the effect (and bias) of allowing the user to freely alter image processing outcomes needs to be rigorously examined and reported.**Blinded image analysis:** Software packages should include built‐in support for image filename anonymization to blind the user from an image\'s study group assignment to minimize bias as images are analyzed.**Semi‐automated curation:** Image quality and marker expression can change between study groups, which could bias automated segmentation and results. Image analysis programs should, therefore, build on previous efforts[97](#micc12520-bib-0097){ref-type="ref"} to include the option to efficiently curate segmentation within a study group in a blinded fashion in regions where automated analysis fails. While some of the programs allows for a degree of curation with adjusting image processing parameters, there is no examination with how this can bias results if the researcher changes these parameters between study groups or images.**Built‐in detection of insufficient sampling:** It is important for the image datasets to sample enough of the microvasculature for valid metric quantification. For simple metrics, such as vessel length density or VAF, a simple examination of variance and power analysis can determine whether more images of a biological sample are required. However, for more advanced quantification metrics, such as lacunarity and fractal dimension, or graph theory‐based metrics, the metrics become nonsensical if the field of view is too small and not enough vascular network sampled. These metrics need to be studied and predictive algorithms developed to warn the user if the dataset is at risk for yielding invalid results for advance structural metrics.**Source code and dataset availability:** While most published software packages will provide source code and data upon request, we believe that it should be standard to make both freely available for download on long‐term hosting platforms such as Github, Bitbucket, or an institutional repository. This removes any barrier to iterate on previous work and facilitates comparison of software packages. Freely available image datasets will also standardize the validation process and enhance progress within the field in the same way standard datasets have with analyzing retina microvessels in fundus imaging.[109](#micc12520-bib-0109){ref-type="ref"}, [110](#micc12520-bib-0110){ref-type="ref"}**Novel metrics:** More metrics need to be developed to describe all observed complexities found in the network structure, with the long‐term view that a sufficient number of metrics for characterizing the microvasculature would allow for the successful creation of in silico artificial networks that are indiscernible from experimentally derived microvascular network structures. Any degree short of this reproduction would mean that information is being lost by the current metric set. Techniques for developing new metrics can be guided from the field of feature engineering.[111](#micc12520-bib-0111){ref-type="ref"}

Without tackling these issues, new software programs are merely presented to research scientists "as is" without allowing them to make informed decisions on how to produce high‐quality unbiased results. We argue that until these issues are dealt with, the use of these packages has the risk of leading to a significant error rate in microvascular research: where the software reveals a positive error with a quantifiable change between groups where none existed, or even worse, where research is not pursued based on a negative error where no change is observed between study groups where one exists.

4.6. Applications of machine learning, graph theory, and modeling in quantifying microvascular architecture {#micc12520-sec-0013}
-----------------------------------------------------------------------------------------------------------

Metric effectiveness not only needs to be evaluated on an individual basis, but the effectiveness of a given collection of metrics in combination needs to be evaluated. This can start with examining covariance matrices of metrics from in silico and biological datasets to evaluate how much unique information they bring relative to one another. Effectiveness of metric sets could be evaluated using principal components analysis, partial least squares, or more advanced methods of feature selection techniques from the field of feature engineering,[108](#micc12520-bib-0108){ref-type="ref"} especially when applied to in silico artificial networks where basic parameters (vessel length density, vessel diameter, branchpoints density, tortuosity, connectivity) can be changed in a controlled fashion. Further research must be conducted on what makes an effective metric in an unbiased fashion, and consensus much be reached on normalization of metrics so they can be used in a standardized way, such as the disagreement on how to normalize branchpoints counts (by image area, vessel length, or binned vessel diameter). This will depend on the development and pairing of fully parametrized in silico models[112](#micc12520-bib-0112){ref-type="ref"} (Table [6](#micc12520-tbl-0006){ref-type="table"}), structural models of models of vascular flow,[113](#micc12520-bib-0113){ref-type="ref"}, [114](#micc12520-bib-0114){ref-type="ref"} and models of predictive tissue oxygenation[115](#micc12520-bib-0115){ref-type="ref"} with biological experiments[116](#micc12520-bib-0116){ref-type="ref"} to fully connect metrics of microvascular structure to biological behaviors.

###### 

Computation Models of Microvascular Architecture

  Description                                                                                     Language      Method                         Type                                                            Validation
  ----------------------------------------------------------------------------------------------- ------------- ------------------------------ --------------------------------------------------------------- --------------------------------------------------------------------------------
  Particle‐based EC Network[284](#micc12520-bib-0284){ref-type="ref"}                             C++           ABM, CPM                       Vasculogenesis                                                  QT to classic CPM
  Retina ABM[285](#micc12520-bib-0285){ref-type="ref"}                                            NetLogo       ABM                            Retinal developing vasculature                                  QT comparison retinal BD
  3D CPM of Tumor Growth[286](#micc12520-bib-0286){ref-type="ref"}                                CompuCell3D   ABM, CPM                       Tumor angiogenesis                                              QL to Macklin et al.[287](#micc12520-bib-0287){ref-type="ref"}
  ABM for Disruption of Vasculogenesis[288](#micc12520-bib-0288){ref-type="ref"}                  CompuCell3D   ABM                            Vasculogenesis                                                  QT to BD with AngioTool[78](#micc12520-bib-0078){ref-type="ref"}
  3D Sprouting Angiogensis[289](#micc12520-bib-0289){ref-type="ref"}                              NS            ABM                            Sprouting angiogenesis                                          QT metrics within BD range
  Hypoxic Vessel Sprouting[290](#micc12520-bib-0290){ref-type="ref"}                              NS            ABM Hybrid                     Any 2D or 3D vessel formation in a tissue                       QT comparison with BD
  Tumor Angiogenesis and Patterning[291](#micc12520-bib-0291){ref-type="ref"}                     NS            ABM Hybrid                     Sprouting angiogenesis                                          QT metrics within BD range
  Angiogenesis with Discrete Random Walks[292](#micc12520-bib-0292){ref-type="ref"}               NS            ABM Hybrid                     Tumor angiogenesis                                              QL assessment of simulation results
  ABM of Tumor Angiogenesis and Regression^293^                                                   NS            ABM Hybrid                     Tumor angiogenesis and regression                               QL to BD
  3D Phase Field ABM of Vascular Networks^294^                                                    NS            ABM Hybrid                     3D Angiogenesis                                                 QL to basic theoretical behavior
  Adaptive Network with Flow^295^                                                                 C             Stochastic Hybrid model        Flow, oxygen transport, and adaptation of existing network      Thorough quantitative comparison to experimental results across all categories
  Multiphase Tumor Angiogenesis Growth^296^                                                       CAST3M        Continuum Discrete             Tumor growth                                                    QT comparison with BD
  Vessel Generator for Cell‐colocalization (CIRCOAST)[135](#micc12520-bib-0135){ref-type="ref"}   MATLAB        Structural Descriptive Model   Static adult microvascular network for basic model validation   QT metrics within BD range
  Tumor Angiogenesis with Blood and Interstitial Flow^297^                                        NS            Hybrid                         Tumor growth                                                    QT metrics within BD range

ABM, Agent‐based model; BD, biological data; CPM, cellular pots model; QL, qualitative; QT, quantitative; NS, not specified.

John Wiley & Sons, Ltd

Blood vessel networks can be abstracted as a series of branchpoints, or nodes, with varying connectivity with each other. Previous work has explored the basic concept of abstracting the microvasculature as a graph,[117](#micc12520-bib-0117){ref-type="ref"} and we believe there are a wealth of relevant metrics that could be applied from quantifying graph networks (Figure [6](#micc12520-fig-0006){ref-type="fig"}). Examples include metrics measuring centrality of each node,[118](#micc12520-bib-0118){ref-type="ref"} scoring the relative importance of edges in connecting nodes, connective redundancy,[119](#micc12520-bib-0119){ref-type="ref"} and information diffusion.[120](#micc12520-bib-0120){ref-type="ref"} Machine learning methods such as convolution neural networks and other techniques[121](#micc12520-bib-0121){ref-type="ref"} have also been applied to graph networks.[122](#micc12520-bib-0122){ref-type="ref"} Previous applications of network tomography outside of biomedical research,[123](#micc12520-bib-0123){ref-type="ref"} such as internet tomography,[124](#micc12520-bib-0124){ref-type="ref"} may be a pertinent source of applicable methods for characterizing complex microvascular networks.

![Novel image analysis metrics by analyzing the microvasculature with graph theory. A, Confocal microscopy image of the murine retinal deep vasculature, with CD105 marking ECs (white; scale bar = 50 μm). B, Image analyzed with basic segmentation, skeletonization, and branchpoints classification, with vessel centerline/skeleton (white), branchpoints (red), and EP (turquoise). C, Conversion of vasculature into a graph, with branchpoints indicated as "nodes" (blue) and vessel segments as "edges" (gray). D, Visual summary of types of metrics to quantify graphs, with removed edges representing change to network after a blood vessel has regressed or experiences obstructed flow](MICC-26-na-g006){#micc12520-fig-0006}

4.7. Relevant techniques from related network architectures {#micc12520-sec-0014}
-----------------------------------------------------------

Analysis of full feature microvascular architectures can also benefit from adapting techniques used to analyze similar network structures. A prime example is fundus imaging of human retinal vascular networks: Although such images fail to resolve capillary portions of the microvascular network, this application has been extensively explored due to its established clinical significance in evaluating eye disease and a collection of systemic diseases,[125](#micc12520-bib-0125){ref-type="ref"} with a plethora of methods developed to segment, quantify, and validate vessel architecture.[126](#micc12520-bib-0126){ref-type="ref"} Indeed, a machine learning‐based classification pipeline for fundus images has recently been approved by the FDA for diagnosis of diabetic retinopathy.[127](#micc12520-bib-0127){ref-type="ref"} Methods used in the processing and quantification of neuronal network image datasets[128](#micc12520-bib-0128){ref-type="ref"} may yield useful techniques for analyzing microvascular networks.[129](#micc12520-bib-0129){ref-type="ref"} In vivo clinical imaging techniques, such as micro‐CT[130](#micc12520-bib-0130){ref-type="ref"} of lung vascular networks, may also yield insight into extending 2D imaging and quantification into the third dimension.[131](#micc12520-bib-0131){ref-type="ref"}

Although this review focuses on 2D image quantification techniques, many of the imaging modalities mentioned acquire data in 3D directly, or through a series of 2D slices. Over the long term, the field would most benefit from acquiring and analyzing 3D datasets to eliminate any confounding phenomena that arises from analyzing a 2D‐projected representation of complex 3D structures. Such 2D abstractions can lead to altered metrics, such as false branch points where vessels appear to overlap in 2D but exist at distinct elevations in 3D, introducing error to other metrics such as segment length. Furthermore, the 3D orientation of vessel segments relative to one another is especially important when characterizing local tissue oxygenation.[89](#micc12520-bib-0089){ref-type="ref"} An in‐depth examination of how 2D structural metrics can characterize a projected 3D structure like a microvascular network would also be necessary to understand the trade‐offs and reveal what information is missed with this simplification.

4.8. Statistics to analyze microvascular interactions: beyond generic {#micc12520-sec-0015}
---------------------------------------------------------------------

The metrics covered in this review require basic 2‐sample or multi‐sample statistical tests to determine whether there is a difference in structure and morphology of vascular networks between study groups. Yet there are also new statistics being developed based on modeling null distributions (output if the null hypothesis is true and there is no difference between groups) that could be extended to quantifying the microvascular architecture. A prime example of this is a technique to measure cellular recruitment with a given cell type and the vascular network,[132](#micc12520-bib-0132){ref-type="ref"} that maintains validity in conditions where generic statistics fail. While cell recruitment has been analyzed,[97](#micc12520-bib-0097){ref-type="ref"} previous metrics of cell‐to‐cell colocalization events fails to properly measure changes in cell recruitment if there are changes to vascular density or cell density across study groups. This confounding phenomenon will lead to false positives when testing between study groups[132](#micc12520-bib-0132){ref-type="ref"}: instances where the test indicates there is a significant change in cell recruitment, when in reality there is none. Null modeling of random cell placement is used to avoid the deficiencies of generic statistics, and we believe this modeling approach could be applied to evaluating perivascular cell recruitment to blood vessel architecture using an in silico model and provide researchers with a more robust statistical hypothesis test for analyzing microvessel architecture.

PERSPECTIVES {#micc12520-sec-0016}
============

The microvasculature is implicated in pathogenesis and maintenance of the deadliest maladies of the modern world. Understanding microvasculature\'s function, adaptation, and contribution to disease is enabled by the application of metrics that quantify changes to microvascular network architecture in in vivo, in vitro, and in silico model systems. We highlight opportunities to further the field by improving scientific rigor and reproducibility through the development and validation of software that reliably, comprehensively, and in an automated manner, characterizes the complexities of microvascular architecture using pre‐existing and novel metrics.
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